MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer

Garajová I, Giovannetti E, Caponi S, van Zweeden A, Peters GJ.

Curr Pharmacol Rep (2015) 1:223–233

continue reading →

Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells

Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E

Curr Drug Targets. 2014;15(14):1331-40

continue reading →

New strategies and applications for Drugs Targeting EGFR and C-Met

Giovannetti E, Leon LG.

Curr Drug Targets. 2014;15(14):1261-2

continue reading →

AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients

Avan A, Avan A, Le Large TY, Mambrini A, Funel N, Maftouh M, Ghayour-Mobarhan M, Cantore M, Boggi U, Peters GJ, Pacetti P, Giovannetti E
PLoS One. 2014 Sep 19;9(9):e108057. doi: 10.1371/journal.pone.0108057. eCollection 2014

continue reading →

Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer

Garajova I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E
BioMed Research International 2014;678401

continue reading →

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma

Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E,* van Die I.*
Oncotarget 2014; 30;5(14):5335-49 (*these authors equally contributed to the study)

continue reading →

Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer

Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E
Curr Pharm Biotechnol. 2014; 15(5):475-85

continue reading →

miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells

Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ, Giovannetti E
Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):384-93

continue reading →

SNPs in PI3K–PTEN–mTOR and Brain Metastases in NSCLC – Letter

Avan A, Maftouh M, Avan A, Tibaldi C, Zucali PA, Giovannetti E
Clin Cancer Res 2014; 20(13):3623-4

A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients

Maftouh M, Avan A, Funel N, Paolicchi E, Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, Mambrini A, Boggi U, Cantore M, Milella M, Peters GJ, Reni M, Giovannetti E
Pharmacogenomics 2014;15:609-18. 1

continue reading →

Lactate dehydrogenase acetylation adds another piece to the puzzle of metabolic reprogramming in pancreatic cancer

Sciarrillo R, Minutolo F, Peters GJ, Giovannetti E
Translational Gastrointestinal Cancer. Vol 3, No 2 (April 2014)

Link: www.amepc.org/tgc/article/view/3706/4598
Free full PDF text: click here

CYB5A and autophagy-mediated cell death in pancreatic cancer

Giovannetti E, Giaccone G.
Autophagy 2014;10:697-8

continue reading →

CYB5A role in pancreatic cancer prognosis and autophagy modulation

Giovannetti E,* Wang Q,* Avan A, Funel N, Lagerweij T, Lee JH, Caretti V, van der Velde A, Boggi U, Wang Y, Vasile E, Peters GJ, Wurdinger T, Giaccone G
JNCI – J Natl Cancer Inst. 2014;106(1):djt346. (*these authors equally contributed to the study)

continue reading →